Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Neurosurg Focus ; 25(5): E5, 2008.
Artigo em Inglês | MEDLINE | ID: mdl-18980479

RESUMO

OBJECT: Oxidative stress leading to lipid peroxidation is a major cause of secondary injury following spinal cord injury (SCI). The objectives of this study were to determine the duration of lipid peroxidation following acute SCI and the efficacy of short-and long-term administration of methylprednisolone on decreasing lipid peroxidation. METHODS: A total of 226 female Wistar rats underwent clip-compression induced SCI. In the first part of the study, spinal cords of untreated rats were assayed colorimetrically for malondialdehyde (MDA) to determine lipid peroxidation levels at various time points between 0 and 10 days. In the second part of the study, animals were treated with methylprednisolone for either 24 hours or 7 days. Control animals received equal volumes of normal saline. Treated and control rats were killed at various time points between 0 and 7 days. RESULTS: The MDA levels initially peaked 4 hours postinjury. By 12 hours, the MDA levels returned to baseline. A second increase was observed from 24 hours to 5 days. Both peak values differed statistically from the trough values (p < 0.008). The methylprednisolone reduced MDA levels (p < 0.04) within 12 hours of injury. No effect was seen at 24 hours or later. CONCLUSIONS: The results of this study indicate that oxidative stress persists for 5 days following SCI in rats, and although methylprednisolone reduces MDA levels within the first 12 hours, it has no effect on the second lipid peroxidation peak.


Assuntos
Peroxidação de Lipídeos/efeitos dos fármacos , Metilprednisolona/uso terapêutico , Fármacos Neuroprotetores/uso terapêutico , Traumatismos da Medula Espinal/tratamento farmacológico , Análise de Variância , Animais , Peso Corporal/efeitos dos fármacos , Colorimetria/métodos , Modelos Animais de Doenças , Masculino , Ratos , Ratos Wistar , Fatores de Tempo
2.
Am J Trop Med Hyg ; 89(5): 819-823, 2013 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-24197172

RESUMO

To date, existing studies focus largely on the economic detriments of malaria. However, if we are to create suitable incentives for larger-scale, more sustained anti-malaria efforts from a wider group of stakeholders, we need a much better understanding of the economic benefits of malaria reduction and elimination. Our report seeks to rectify this disjuncture by showing how attaining the funding needed to meet internationally agreed targets for malaria elimination would, on conservative assumptions, generate enormous economic improvements. We use a cost-benefit analysis anchored in Global Malaria Action Plan projections of malaria eradication based on fully met funding goals. By calculating the value of economic output accrued caused by work years saved and subtracting the costs of intervention, we find that malaria reduction and elimination during 2013-2035 has a 2013 net present value of US $208.6 billion.


Assuntos
Erradicação de Doenças/economia , Saúde Global/economia , Malária/economia , Malária/prevenção & controle , Antimaláricos/síntese química , Antimaláricos/uso terapêutico , Análise Custo-Benefício/estatística & dados numéricos , Erradicação de Doenças/organização & administração , Humanos , Cooperação Internacional , Malária/tratamento farmacológico
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa